bofutrelvir   Click here for help

GtoPdb Ligand ID: 11070

Synonyms: compound 11a [PMID: 32321856] | DC-402234 | DC402234 | FB-2001 | FB2001
PDB Ligand
Compound class: Synthetic organic
Comment: Compound 11a is an inhibitor of SARS-CoV-2 main protease (Mpro) [1]. It interacts with Cys145 of Mpro and it inhibits both protease activity and SARS-CoV-2 infectivity in vitro. Given its low in vivo toxicity and favourable PK profile, 11a is considered to be a valuable lead candidate. Based on commentary in a review by Zhao et al. (2022) [3], compound 11a appears to be the Mpro inhibitor that is being tested in clinical trials as FB2001 (and which is also known as DC402234). The chemical structure of this compound matches that provided for the INN bofutrelvir.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 4
Rotatable bonds 11
Topological polar surface area 120.16
Molecular weight 452.24
XLogP 3.7
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@@H](NC(=O)c1cc2c([nH]1)cccc2)CC1CCCCC1
Isomeric SMILES O=C[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@@H](NC(=O)c1cc2c([nH]1)cccc2)CC1CCCCC1
InChI InChI=1S/C25H32N4O4/c30-15-19(13-18-10-11-26-23(18)31)27-24(32)21(12-16-6-2-1-3-7-16)29-25(33)22-14-17-8-4-5-9-20(17)28-22/h4-5,8-9,14-16,18-19,21,28H,1-3,6-7,10-13H2,(H,26,31)(H,27,32)(H,29,33)/t18-,19-,21-/m0/s1
No information available.
Summary of Clinical Use Click here for help
Bofutrelvir (FB2001) has progressed to clinical evaluation for potential to treat SARS-CoV-2 infection (COVID-19).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04766931 The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection Phase 1 Interventional Frontier Biotechnologies Inc.
NCT05415241 Exploratory Study of Aerosol Inhalation of FB2001 for Post-exposure Prophylaxis of COVID-19 Close Contacts Phase 1/Phase 2 Interventional Ruijin Hospital
NCT05445934 Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study) Phase 2/Phase 3 Interventional Frontier Biotechnologies Inc.